Mezzion Pharma Co.Ltd (140410) — Working Capital to Net Assets Ratio
Mezzion Pharma Co.Ltd (140410) has a Working Capital to Net Assets ratio of -197.7% as of December 2025. Working capital of ₩-33.99 Billion (current assets of ₩45.59 Billion minus current liabilities of ₩79.57 Billion) is measured against net assets of ₩17.19 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 140410 equity financing ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Mezzion Pharma Co.Ltd Working Capital to Net Assets (2012–2025)
This chart shows how Mezzion Pharma Co.Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2012 to 2025. As of December 2025, the ratio stands at -197.7%, reflecting working capital of ₩-33.99 Billion against net assets of ₩17.19 Billion KRW. Check Mezzion Pharma Co.Ltd (140410) tangible net worth to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Mezzion Pharma Co.Ltd (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Mezzion Pharma Co.Ltd from 2012 to 2025, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Mezzion Pharma Co.Ltd stock valuation.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -197.7% | ₩-33.99 Billion | ₩17.19 Billion | ₩45.59 Billion | ₩79.57 Billion | ▼ -230.8 pp |
| 2024 | 33.1% | ₩15.26 Billion | ₩46.06 Billion | ₩41.93 Billion | ₩26.67 Billion | ▼ -39.5 pp |
| 2023 | 72.6% | ₩44.63 Billion | ₩61.44 Billion | ₩74.24 Billion | ₩29.62 Billion | ▼ -2.9 pp |
| 2022 | 75.5% | ₩19.82 Billion | ₩26.24 Billion | ₩45.90 Billion | ₩26.08 Billion | ▲ +2.8 pp |
| 2021 | 72.7% | ₩45.68 Billion | ₩62.79 Billion | ₩64.17 Billion | ₩18.50 Billion | ▼ -6.7 pp |
| 2020 | 79.5% | ₩45.15 Billion | ₩56.81 Billion | ₩60.67 Billion | ₩15.51 Billion | ▼ -10.0 pp |
| 2019 | 89.5% | ₩38.34 Billion | ₩42.83 Billion | ₩51.85 Billion | ₩13.51 Billion | ▼ -1.7 pp |
| 2018 | 91.2% | ₩52.28 Billion | ₩57.32 Billion | ₩70.02 Billion | ₩17.74 Billion | ▼ -2.8 pp |
| 2017 | 94.1% | ₩50.01 Billion | ₩53.17 Billion | ₩70.50 Billion | ₩20.49 Billion | ▼ -53.1 pp |
| 2016 | 147.2% | ₩77.71 Billion | ₩52.81 Billion | ₩94.19 Billion | ₩16.48 Billion | ▲ +13.5 pp |
| 2015 | 133.7% | ₩83.61 Billion | ₩62.54 Billion | ₩97.33 Billion | ₩13.72 Billion | ▲ +44.3 pp |
| 2012 | 89.4% | ₩56.63 Billion | ₩63.34 Billion | ₩59.57 Billion | ₩2.94 Billion | — |